Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 25, 2022 09:00 ET | Source: Enterin Inc.

Enterin to Announce Top-Line Results From the Phase 2b Study for Parkinson's Disease

PHILADELPHIA, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and...
January 11, 2022 15:00 ET | Source: Enterin Inc.

Enterin and Their Collaborators at NIH Announce That Alpha-Synuclein, the Culprit in Parkinson's Disease, is Core and Central to Normal Immune Function

PHILADELPHIA, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and...
January 10, 2022 09:00 ET | Source: Enterin Inc.

Enterin Announces Appointment of Dr. Patrik Brundin to Its Scientific Advisory Board

PHILADELPHIA, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and...
November 19, 2021 09:00 ET | Source: Enterin Inc.

Enterin Announces Publication of Exciting Discoveries About the Enterin Nervous System

PHILADELPHIA, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held Philadelphia-based clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and...
October 11, 2021 07:00 ET | Source: Amydis, Inc.

Amydis Awarded $3 Million NIH Grant to Explore Novel Alpha Synuclein Retinal Tracer in Non-human Primate Models of Parkinson’s Disease and Multiple System Atrophy

SAN DIEGO, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye,...
September 13, 2021 09:00 ET | Source: Enterin Inc.

Enterin Announces Appointment of Dr. Roger Mills to Its Board of Directors

PHILADELPHIA, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Enterin, Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and...
July 27, 2021 08:00 ET | Source: AFFiRiS AG

AC Immune acquires AFFiRiS’ Specific Active Immunotherapy (SAIT) anti-alpha-synuclein programs targeting neurodegenerative diseases

AFFiRiS to receive AC Immune stock valued at USD 58.7 million in exchange for its portfolio of therapeutics targeting alpha-synuclein and USD 5 million in cashAFFiRiS to focus on partnering to further...
April 26, 2021 07:00 ET | Source: Amydis, Inc.

Amydis Announces Successful Completion of Pre-IND Meeting with the FDA for the Development of a First-in-Class Retinal Tracer for the Diagnosis of Alpha-synucleinopathies

SAN DIEGO, April 26, 2021 (GLOBE NEWSWIRE) -- Amydis Inc., a leading ocular tracer biotechnology company with a broad portfolio of diagnostic candidates for detection of neurodegenerative diseases...
August 11, 2020 07:00 ET | Source: Amydis, Inc.

Amydis Awarded Michael J. Fox Foundation Grant to Accelerate Development of an Alpha-Synuclein Retinal Tracer to Diagnose Parkinson’s Disease Through the Eye

SAN DIEGO, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Amydis, Inc., a biotechnology company developing a new class of diagnostics to enable the early detection of neurological diseases through the retina,...
February 22, 2019 08:00 ET | Source: Voyager Therapeutics, Inc.

Voyager Therapeutics and AbbVie Announce Collaboration to Develop Vectorized Antibodies to Treat Parkinson’s Disease and Other Synucleinopathies

Deal expands collaborative efforts on vectorized antibodies to target pathological species of alpha-synuclein Voyager to receive $65 million upfront and up to $245 million in preclinical and Phase 1...